Free complement and complement containing extracellular vesicles as potential biomarkers for neuroinflammatory and neurodegenerative disorders
| Autor: | Burgelman, Marlies, Dujardin, Pieter, Vandendriessche, Charysse, Vandenbroucke, Roosmarijn |
|---|---|
| Rok vydání: | 2023 |
| Předmět: |
FACTOR-H
extracellular vesicle (EV) Immunology Biology and Life Sciences EARLY VALIDATION Alzheimer's disease multiple sclerosis IDENTIFIES VARIANTS neuroinflammation ALZHEIMERS-DISEASE PLASMA CLUSTERIN CONCENTRATION CEREBROSPINAL-FLUID ANALYSIS COGNITIVE DECLINE Medicine and Health Sciences biomarker Immunology and Allergy complement GENOME-WIDE ASSOCIATION TERMINAL COMPONENT MULTIPLE-SCLEROSIS PATIENTS |
| Zdroj: | FRONTIERS IN IMMUNOLOGY |
| ISSN: | 1664-3224 |
| DOI: | 10.3389/fimmu.2022.1055050 |
| Popis: | The complement system is implicated in a broad range of neuroinflammatory disorders such as Alzheimer’s disease (AD) and multiple sclerosis (MS). Consequently, measuring complement levels in biofluids could serve as a potential biomarker for these diseases. Indeed, complement levels are shown to be altered in patients compared to controls, and some studies reported a correlation between the level of free complement in biofluids and disease progression, severity or the response to therapeutics. Overall, they are not (yet) suitable as a diagnostic tool due to heterogeneity of reported results. Moreover, measurement of free complement proteins has the disadvantage that information on their origin is lost, which might be of value in a multi-parameter approach for disease prediction and stratification. In light of this, extracellular vesicles (EVs) could provide a platform to improve the diagnostic power of complement proteins. EVs are nanosized double membrane particles that are secreted by essentially every cell type and resemble the (status of the) cell of origin. Interestingly, EVs can contain complement proteins, while the cellular origin can still be determined by the presence of EV surface markers. In this review, we summarize the current knowledge and future opportunities on the use of free and EV-associated complement proteins as biomarkers for neuroinflammatory and neurodegenerative disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|